Ahmed Mousa
Chief Executive Officer Vicore Pharma Holding
Seminars
Wednesday 2nd December 2026
From Epithelial Repair to Durable Benefit: AT2 Receptor Agonism as an Upstream Intervention in Fibrotic Disease
12:00 pm
- AT2 receptor agonism restores the protective arm of the renin–angiotensin system, promoting epithelial resilience and repair following alveolar injury – an early pathogenic event that can contribute to inflammation, metabolic dysfunction, vascular remodelling, and fibrosis
- Positioning the AT2 receptor as an upstream modulatory node at the intersection of fibrotic remodelling: where diverse pathological insults converge on shared profibrotic pathways, while disease-specific biology defines therapeutic opportunity and indication boundaries
- Translational evidence for AT2 receptor agonism in fibrotic disease in preclinical and early clinical studies
Wednesday 2nd December 2026
Panel Discussion: Defining Cross-Indication Expansion Strategies to Maximize the Clinical & Commercial Potential of Antifibrotic Therapies
2:30 pm
- Determining when preclinical evidence is sufficiently robust to justify expanding an antifibrotic program into additional fibrotic indications rather than remaining disease-specific
- Identifying the biological, translational, regulatory, and commercial factors that should guide indication prioritization, including shared mechanisms, biomarker availability, clinical endpoints, and unmet need
- Exploring whether future antifibrotic programs should be intentionally designed as multi-indication assets from discovery or whether expansion should remain a staged, indication-by-indication strategy
